175 related articles for article (PubMed ID: 36701413)
1. Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning.
Ha CSR; Müller-Nurasyid M; Petrera A; Hauck SM; Marini F; Bartsch DK; Slater EP; Strauch K
PLoS One; 2023; 18(1):e0280399. PubMed ID: 36701413
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
3. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
4. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
5. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
[TBL] [Abstract][Full Text] [Related]
6. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
7. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
[TBL] [Abstract][Full Text] [Related]
8. Advances in pancreatic cancer research: moving towards early detection.
He XY; Yuan YZ
World J Gastroenterol; 2014 Aug; 20(32):11241-8. PubMed ID: 25170208
[TBL] [Abstract][Full Text] [Related]
9. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
10. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
11. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
12. Whole genome sequencing identifies rare germline variants enriched in cancer related genes in first degree relatives of familial pancreatic cancer patients.
Tan M; Brusgaard K; Gerdes AM; Mortensen MB; Detlefsen S; Schaffalitzky de Muckadell OB; Joergensen MT
Clin Genet; 2021 Nov; 100(5):551-562. PubMed ID: 34313325
[TBL] [Abstract][Full Text] [Related]
13. Variation in precursor lesions of pancreatic cancer among high-risk groups.
Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ;
Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer early detection: expanding higher-risk group with clinical and metabolomics parameters.
Urayama S
World J Gastroenterol; 2015 Feb; 21(6):1707-17. PubMed ID: 25684935
[TBL] [Abstract][Full Text] [Related]
15. Progress report: familial pancreatic cancer.
Mintziras I; Bartsch DK
Fam Cancer; 2019 Jul; 18(3):359-362. PubMed ID: 30796632
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
17. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
19. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.
Bhasin MK; Ndebele K; Bucur O; Yee EU; Otu HH; Plati J; Bullock A; Gu X; Castan E; Zhang P; Najarian R; Muraru MS; Miksad R; Khosravi-Far R; Libermann TA
Oncotarget; 2016 Apr; 7(17):23263-81. PubMed ID: 26993610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
